UK Approves Mounjaro for Obesity Treatment, Offering Alternative to Wegovy

NICE recommends Eli Lilly's tirzepatide for patients with high BMI and weight-related conditions, without a usage time limit.

Mounjaro, a GLP-1 agonist, is approved for patients with a BMI of 35 and at least one weight-related health issue.
Clinical trials show Mounjaro users lost 22.5% of body weight over 72 weeks, outperforming Wegovy.
NICE draft guidance allows Mounjaro to be prescribed by GPs, potentially increasing its accessibility.
The drug is recommended for long-term use, unlike Wegovy which has a two-year limit.
Cost and availability details are still under negotiation, with final NICE guidance expected in October.